Molecular Insight expands portfolio | Chemical & Engineering News
Volume 85 Issue 5 | p. 24 | Concentrates
Issue Date: January 29, 2007

Molecular Insight expands portfolio

Department: Business

Molecular Insight Pharmaceuticals has licensed Onalta, a radiolabeled peptide for the treatment of pancreatic neuroendocrine and carcinoid tumors, from Novartis. Onalta, which has orphan drug status from FDA, has been studied in Phase I and II clinical trials. Earlier this month, Molecular Insight added another radiotherapeutic to its portfolio by licensing Solazed, Bayer Schering Pharma's small molecule labeled with iodine-131 for the treatment of malignant melanoma. Financial terms of the deals were not disclosed, but both include upfront, milestone, and royalty payments.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment